MoA video for a U.S. product launch of a breakthrough oncology drug.
This 3D mechanism-of-action animation has been created for the U.S. product launch of Abstral® (fentanyl) Sublingual Tablets, the treatment for Breakthrough Cancer Pain (BTcP).
We began the video with the introduction of the cause of pain, highlighting metastatic bone cancer, before showcasing the mechanism-of-action (MoA) of the drug and its significant effect on breakthrough cancer pain.
Deliverables
3D animation
Product Shots
High-Res Images
Storyboard
Client
Galena Biopharma
Brand
Abstral®
Breakthrough cancer pain (BTcP) is defined as a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain.
Breakthrough cancer pain occurs in the majority of patients who are already receiving chronic, long-acting opioid pain management and yet have episodes of severe tumor- and treatment-related cancer pain.
Director, Oncology Marketing, Galena Biopharma, Oregon, USA
Tissue Analytics
Animation for a medtech firm developing a next-generation equipment for cancer research and tissue analytics.
Suite 6, Claremont House,
22-24, Claremont Rd.,
Surbiton, Surrey,
KT6 4QU, UK
